125 related articles for article (PubMed ID: 37530339)
1. Pediatric and adolescent chronic myeloid leukemia: A follow-up study in Western India.
Vanik SA; Jetly D; Parikh B; Dhandapani K; Bezbaruah R
Indian J Pathol Microbiol; 2023; 66(3):560-563. PubMed ID: 37530339
[TBL] [Abstract][Full Text] [Related]
2. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of Sokal, Hasford and EUTOS prognostic scoring systems in chronic myeloid leukemia].
Feng G; Wang J; Jiang Y; Li Y; Ding M; Wang N; Wang X
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):743-6. PubMed ID: 25152126
[TBL] [Abstract][Full Text] [Related]
4. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
[TBL] [Abstract][Full Text] [Related]
5. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
Kanakasetty GB; Thanky AH; Kuntegowdanahalli L; Dasappa L; Jacob L; Mallekavu SB; Lakkavalli R; Kadabur L; Antapura R
Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):375-381. PubMed ID: 28502460
[TBL] [Abstract][Full Text] [Related]
6. Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
Huang J; Wang L; Chen L; Qun H; Yajing X; Fangping C; Xielan Z
Turk J Haematol; 2017 Mar; 34(1):10-15. PubMed ID: 27751981
[TBL] [Abstract][Full Text] [Related]
7. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?
Gurrea Salas D; Glauche I; Tauer JT; Thiede C; Suttorp M
Ann Hematol; 2015 Aug; 94(8):1363-71. PubMed ID: 25894600
[TBL] [Abstract][Full Text] [Related]
8. Factors Affecting Early Molecular Response in Chronic Myeloid Leukemia.
Chikkodi SV; Malhotra P; Naseem S; Khadwal A; Prakash G; Sahu KK; Kumari S; Suri V; Varma N; Varma S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S114-9. PubMed ID: 26297263
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
10. Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.
Ko PS; Yu YB; Liu YC; Wu YT; Hung MH; Gau JP; Liu CJ; Hsiao LT; Chen PM; Chiou TJ; Liu CY; Liu JH
Curr Med Res Opin; 2017 Oct; 33(10):1737-1744. PubMed ID: 28715941
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Monitoring of Chronic Myeloid Leukemia: Chiang Mai University Experience.
Tantiworawit A; Kongjarern S; Rattarittamrong E; Lekawanvijit S; Bumroongkit K; Boonma N; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Norasetthada L
Asian Pac J Cancer Prev; 2016; 17(4):2159-64. PubMed ID: 27221912
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia].
Huang J; Zhao X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 41(8):809-14. PubMed ID: 27600007
[TBL] [Abstract][Full Text] [Related]
13. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
14. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
Zhang XS; Gale RP; Huang XJ; Jiang Q
Leukemia; 2022 Feb; 36(2):482-491. PubMed ID: 34413457
[TBL] [Abstract][Full Text] [Related]
15. Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients.
Qin YZ; Jiang Q; Jiang H; Lai YY; Zhu HH; Liu YR; Jiang B; Huang XJ
Medicine (Baltimore); 2016 Jan; 95(2):e2486. PubMed ID: 26765457
[TBL] [Abstract][Full Text] [Related]
16. The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia.
Iriyama N; Hatta Y; Kobayashi S; Uchino Y; Miura K; Kurita D; Kodaira H; Inoue M; Takei M
Int J Hematol; 2014 Oct; 100(4):379-85. PubMed ID: 25092482
[TBL] [Abstract][Full Text] [Related]
17. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.
Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
Leuk Lymphoma; 2018 May; 59(5):1105-1112. PubMed ID: 28838287
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Three Prognostic Scoring Systems in Predicting the Response and Outcome in Pediatric Chronic Myeloid Leukemia Chronic Phase on Frontline Imatinib.
Ganta RR; Nasaka S; Linga VG; Gundeti S; Maddali LS; Digumarti RR
Indian J Med Paediatr Oncol; 2017; 38(3):282-286. PubMed ID: 29200674
[TBL] [Abstract][Full Text] [Related]
20. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
Schäfer V; White HE; Gerrard G; Möbius S; Saussele S; Franke GN; Mahon FX; Talmaci R; Colomer D; Soverini S; Machova Polakova K; Cross NCP; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3081-3089. PubMed ID: 33677711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
